Previous 10 | Next 10 |
home / stock / alxo / alxo articles
AbbVie (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has a...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an im...
Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation...
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers repo...
U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday. Shares of United Airlines Holdings, Inc. (NASDAQ: UAL) rose ...
Over the past twenty days of trading, ALX Oncology Holdings Inc. (NASDAQ: ALXO), from February 09, 2024 to March 08, 2024 there is a potential Sho...
Thursday, ALX Oncology Holdings (NASDAQ:ALXO) reported a fourth-quarter 2023 EPS loss of $(0.93), missing the consensus of $(0.86). ...
- Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANC...
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. AAR reported ...
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
2024-07-09 15:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...